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The  androgen  receptor (AR) is a signal-transducing 
protein required for sexual differentiation, develop- 
ment,  and  expression of the male  phenotype. A series 
of human AR deletion  mutants  were  created  either by 
site-directed  mutagenesis  using  restriction  enzyme 
digestion, the  polymerase  chain  reaction,  or,  for a se- 
ries of unidirectional  NH2-terminal  deletions,  exonu- 
clease I11 digestion.  Receptor mutants  were  expressed 
in monkey  kidney COS cells as truncated AR proteins 
between 20 and 107 kDa as revealed  on  immunoblots, 
where wild type AR was a doublet of 114 and 108 kDa. 
Subcellular  localization by immunocytochemical stain- 
ing demonstrated  androgen-dependent  nuclear  uptake 
of AR from a perinuclear  region of the cytoplasm. A 
nuclear  targeting  signal  similar  in  sequence  and posi- 
tion  to  the glucocorticoid receptor  and homologous to 
the SV40 large T antigen  was  required  for  androgen- 
induced  nuclear  uptake of wild  type AR. AR mutants 
lacking  the NH2-terminal and/or  steroid  binding do- 
mains  were  constitutively  nuclear  with  reduced tran- 
scriptional  activity.  Transcriptional  activation by  wild 
type AR was androgen-dependent in cotransfection 
studies of CV1 cells  using the  chloramphenicol  acetyl- 
transferase  reporter  gene  linked  to  the mouse mam- 
mary  tumor  virus  promoter. Deletion  mutagenesis re- 
vealed  within  the  NH2-terminal  region a domain re- 
quired  for  full  transcriptional  activity  and  within  the 
steroid  binding  domain, an  inhibitory  function, dele- 
tion of which  yielded a constitutively  active  receptor. 
Inhibition of wild  type AR by  coexpression  with an 
inactive  NHa-terminal  fragment  suggested  competition 
for  nuclear  factors  required  for  transcriptional  regu- 
lation.  These  studies  demonstrate  concerted  interplay 
among the domains of the AR protein in regulating 
gene  transcription. 
The androgen receptor (AR)’ is a transcription enhancer 
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factor that belongs to a superfamily of nuclear receptors whose 
function is dependent upon the binding of cognate steroid 
hormones. Steroid receptors act  as  transcriptional  activators 
by binding hormone regulatory elements of specific  genes to 
trigger a cascade of transcriptional  events (1-4). The func- 
tional domains of these ligand-activated transcription factors 
are undergoing intense investigation and have been clarified 
to varying degrees (5-12). Sequence comparison and deletion 
mutagenesis have revealed three major domains: a  NHp-ter- 
minal region  involved in transcriptional activation; a highly 
conserved, cysteine-rich DNA binding domain; and a car- 
boxyl-terminal steroid binding domain (1, 4). Subsequently, 
signal sequences for nuclear translocation were  recognized in 
the hinge region between the DNA and steroid binding do- 
mains for the glucocorticoid and progesterone receptors (13, 
14).  Sites for receptor dimerization occur within the DNA and 
steroid binding domains of the mouse estrogen receptor (15, 
16). The DNA binding region contains highly conserved 
amino acids critical for receptor function (17),  the importance 
of which  is exemplified by natural  mutations  in the AR gene 
in  a  patient with androgen insensitivity (18, 19) and in the 
vitamin D receptor gene in the syndrome of hypocalcemic 
vitamin D-resistant rickets (20). The variable amino acids 
within the DNA binding domain determine specificity for 
hormone response elements, particularly two amino acids in 
the P box toward the carboxyl side of the first zinc finger 
While the DNA binding domain is absolutely required for 
transcriptional activation (24, 25), dimerization (15, 26), and 
nuclear transport  (14), sequences outside this region are  in- 
volved  in functional activity (27-29). Short acidic regions in 
the  NH2-  and COOH-terminal domains of the glucocorticoid 
receptor have roles in transcriptional activation which are 
position-independent and cooperative (28, 30). Sequences to- 
ward the carboxyl- and NH2-terminal ends of the estrogen 
and progesterone receptors determine receptor specificity for 
target genes in a cell-specific manner (27,  31, 32). Although 
the precise mechanism of transcriptional activation by steroid 
hormones is not well understood, it is likely that cooperative 
interactions occur between liganded activated steroid recep- 
tors  and upstream transcription factors to form active tran- 
scription initiation complexes (33, 34). In this model, the 
transcriptional activator signals are reversibly inhibited by 
the ligand-free steroid binding domain (25 ,  28). 
Studies on the estrogen receptor by King and Greene (35) 
and Welshons et al. (36) challenged the concept of steroid 
receptor transformation in association with receptor translo- 
cation to the nucleus. Their results suggested that nuclear 
localization of steroid receptors is independent of hormone 
binding, a concept later supported by studies on the proges- 
terone receptor (14, 37). However, ligand-dependent nuclear 
(21-23). 
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localization of the glucocorticoid receptor (13, 38) raised the 
possibility that not all steroid receptors follow the same 
pathway to the nucleus. 
In  the present  report, truncation  and deletion mutants of 
the human AR cDNA  were created  to  characterize sequences 
involved in nuclear translocation and  transcriptional activa- 
tion. To functionally  map potential nuclear targeting signals, 
mutant receptors were expressed in COS cells and assayed by 
immunocytochemistry using two polyclonal antibodies di- 
rected against epitopes in the NHP-terminal region of AR 
(39). Ligand-dependent  activation of gene transcription was 
assayed by cotransfection of wild type or mutant receptors 
with a  reporter gene in monkey kidney CV1 cells. 
EXPERIMENTAL  PROCEDURES 
Materials-The following reagents were purchased  ~-threo-[1,2- 
14C]chloramphenicol (40-60 mCi/mmol)  from  ICN Biomedicals; lZ5I- 
protein A and  [3H]methyltrienolone ([17a-methyl-3H]R1881, 80 Ci/ 
mmol)  from  Du  Pont-New  England Nuclear; unlabeled deoxynucleo- 
tide triphosphates, acetyl coenzyme A, and DEAE-dextran from 
Pharmacia LKB Biotechnology Inc.; Taq polymerase from Perkin- 
Elmer Cetus; T4 polynucleotide kinase, T4 DNA ligase, and M13 
bacteriophage from New England Biolabs;  exonuclease 111, T 4  DNA 
ligase, and S1 nuclease from  Promega-Biotec;  restriction  endonucle- 
ases from Bethesda  Research  Laboratories,  Promega Biotec, and New 
England Biolabs; Dulbecco's modified essential medium with high 
glucose and  fetal bovine serum  from GIBCO; X-Omat-AR diagnostic 
x-ray film from Kodak Chemical Co.; buffers and chemicals from 
Fisher,  Bethesda  Research  Laboratories,  and Sigma. Stock  cultures 
of CV1 and COS-7 cells were obtained from the American Type 
Culture Collection. 
Cell Culture  and Biochemical Analysis-Monkey kidney CV1 and 
COS-7 cells were maintained  in 10% fetal calf serum  in Dulbecco's 
minimal  essential medium containing high glucose and  antibiotics. 
COS cells were transfected using the DEAE-dextran method, and 
CV1 cells were transfected  using calcium phosphate  DNA  precipita- 
tion as described  previously  (40). Immunoblot  analysis of AR  mutants 
expressed in  COS cells  was performed as described by Yarbrough et  
al. (40). Binding of [3HJR1881 was measured after culturing trans- 
fected COS cells in serum-free medium 1 day before harvest. Cells 
were incubated with  5 nM [3H]R1881 for 2 h at  37 "C in  the  presence 
or absence of 100-fold excess unlabeled R1881. Free steroid was 
removed, and  the cells were washed in phosphate-buffered  saline  and 
harvested  in  SDS  sample buffer. Aliquots were counted for  radioac- 
tivity  with specific binding  representing  the difference  between counts 
in  the presence and absence of excess  unlabeled hormone. 
Recombinant Plasmids  and  PCR-mediated Mutagenesis-The  full- 
length human AR coding sequence was constructed in pCMV by 
the  first  exon  (41)  and a partial 3' cDNA  clone (42).  AR1  (p5HBhAR- 
ligating three  fragments of 5' overlapping genomic clones containing 
A) was made by subcloning the  full-length  human AR cDNA BgfII- 
BspHI  blunt-ended  fragment  into BglII-Hind111 blunt-ended  restric- 
tion  sites of the  eukaryotic  expression vector  pCMV5  (43). AR mu- 
tants in pCMV5  are driven by the  human cytomegalovirus (Towne 
strain)  early gene promotor  and  contain  the  human  growth  hormone 
transcription  termination  and  polyadenylation signals. Mutants AR2 
(amino  acids 72-919), AR3  (amino  acids 141-919), and AR4 (amino 
acids 338-919) are  NH2-terminal  deletions of ARl prepared by uni- 
directional exonuclease I11 digestion as recommended by Promega 
Biotec (44). A translation initiation Kozak sequence was inserted 
into  the BglII site of AR1 prior to  the exonuclease I11 digestions,  AR5 
(amino  acids 507-919) lacks  most of the  NH?-terminal  domain  and 
was created by inserting  the  KpnI-BamHI  fragment of AR1 into  the 
KpnI-BamHI  sites of pCMV5. Human AR contains an  endogenous 
translation  initiation sequence at methionine 507 which acts as an 
initiation  site  for AR5. AR6  (amino  acids 566-919) is a partial  clone 
used  in the initial  characterization of AR cDNA (42). Mutants AR7, 
-8, -9, and -IO were created using site-directed mutagenesis as de- 
scribed below. ARl l  (amino  acids 1-660) was  made by digesting ARl 
with TthI11, blunt-ended, and digested with Smul to produce  a 
receptor lacking the steroid binding  domain. AR12 (amino  acids 1- 
503) was created by digesting ARl with KpnI  and  BamHI  to  delete 
the DNA and  hormone  binding  domains.  The  fragment was blunt- 
ended and religated to produce a vector containing only the NH,- 
terminal region. AR13 (amino acids 507-660) contains the DNA 
binding  domain/hinge region and was made by digestion of AR5  with 
TthI l l   and blunt-ended  and digested  with SmaI.  Truncated  mutants 
were sequenced to verify the  correct reading  frame.  Vector DNA was 
amplified in DH5 01 Escherichia coli cells. 
A rapid  method for site-specific  mutagenesis  using the polymerase 
chain  reaction  (PCR) (45-47) generated AR7, -8, -9, and -10. Oligo- 
nucleotide primers 18-30 nucleotides in length spanned sequences to 
he deleted and contained appropriate terminal restriction enzyme 
sites.  Typical  reactions of 100 pl contained 1 pg of AR1 expression 
vector  DNA and were performed  in five replicate reactions  for  nine 
cycles using  the  conditions of Perkin-Elmer  Cetus.  Reactions were 
initiated a t  95 "C for 5 min, 60 "C for 1 min,  and 72 "C for 10 min for 
two  cycles, followed by nine cycles of 95 "C for 45 s, 60 "C  for 1 min, 
and  72 "C for 10 min  using  3 units of Tuq polymerase/reaction. All 
PCR-generated  fragments were  purified  on  agarose gels, precipitated 
with 100% ethanol, digested with appropriate restriction enzymes, 
ligated back into  the  expression vector AR1 cDNA,  and sequenced to 
ascertain the absence of PCR-generated errors. Low cycle number 
reduced random  PCR  errors  to  undetectable  in  fragments averaging 
400 base  pairs. AR7 (amino  acids 628-919) contains only the hinge 
region and  hormone  binding  domains. AR8 is a full-length receptor 
with a deletion of the  putative  nuclear  targeting signal, amino acids 
628-657. AR9 contains  amino acids 507-919 with a deletion of amino 
acids 628-657 and was constructed by cloning the  KpnI-BamHI of 
AR8 into  the  KpnI-BamHI of pCMV5. ARlO spanning  amino acids 
507-919 has a deletion of 23 amino  acids (715-737) in  the  hormone 
binding domain.  Deletion of this sequence  which contains a putative 
hsp90  binding  site (48) was achieved by PCR  mutagenesis  and  sub- 
cloning the TthI11-Csp45 fragment into the TthI11-Csp45 site of 
AR5. 
The regions of PCR-generated  fragments ligated into AR vectors 
were sequenced taking advantage of the f l  origin of replication in 
pCMV5. Single-stranded  DNA was generated by incubating 100 pl of 
an  overnight  culture of transformed  DH5 E. cofi in $ 5 5  medium (8 
g of Bactotryptone, 5  g of Bacto  yeast 5  g of NaCl (per  liter)) at 37 "C 
for 30 min. For  superinfection, M13K07  helper phage (40 pl, titer 2.8 
X lo-" plaque-forming  units/ml,  Bio-Rad) was added  and  incubated 
for 6-8 h a t  37 "C. Phages  in  the  supernatant were collected after 
pelleting cells a t  12,000 X g for  15  min  and  precipitated by adding 
0.25 volume of 20% polyethylene glycol ( M ,  8,000) and 3.75 M am- 
monium  acetate.  Single-stranded  DNA  was  precipitated  and isolated 
to sequence  using  procedures for M13  sequencing. 
Immunocytochemistry-COS  cells were plated at  50,000 cells/ 
chamber  in  two-chamber glass  slides and, 24 h later,  transfected with 
pCMV5  containing wild type or mutant AR cDNA using the  DEAE- 
dextran procedure  (0.5 pg of DNA/well).  Immediately after  transfec- 
tion,  the cells were placed in  5% serum containing Dulhecco's minimal 
essential medium containing high glucose. The  next  day,  the medium 
was  replaced  with phenol  red-free,  serum-free medium  with or without 
the  addition of 50 nM R1881, and  the  subsequent  day,  the medium 
was  replaced with  fresh medium of the  same composition and  incu- 
hated for a period of 2 h. Cells were washed in  phosphate-buffered 
saline  (PBS)  and fixed for 10 min with buffer containing  2%  para- 
formaldehyde, 10% sucrose, and 0.1 M sodium phosphate, pH 7.2. 
The  slides were washed in  PBS,  pH 7.4, and permeabilized in 0.2% 
Triton X-100  for 20 min.  After  a  wash in PBS, the cells were treated 
either with 2% bovine serum albumin in PBS for 20 min to block 
nonspecific staining for  immunofluorescence, or 2% normal goat 
serum for peroxidase staining. Cells were incubated with the IgG 
fraction (2-4 pg/ml) or  primary  rabbit  antipeptide  antibody AR52 for 
20 h at 4 "C. In  control  studies,  the IgG fractions of preimmune  and 
peptide-adsorbed  immune  sera were used at  the  same  protein concen- 
trations.  The cells were washed  in PBS followed by incubation with 
either  biotinylated goat anti-rabbit IgG (1:800) for 1 h or fluorescein 
isothiocyanate-conjugated goat  anti-rabbit IgG (1:400; Organon  Tech- 
nika, Cochranville, PA) for 2  h a t  room temperature.  For peroxidase 
staining, avidin biotin peroxidase (ABC, Vector Labs) was used a t  
1:400 dilution for 60 min a s  previousiy described (39, 49). For im- 
munofluorescence, slides were washed in PBS and mounted with 
polyvinyl alcohol/glycerol and  the coverglass was placed. The slides 
were viewed under a Nikon-FXA fluorescent  microscope  using B-2A 
filter. 
RESULTS 
Mutagenesis of AR-The full-length human AR expression 
vector (Fig. 1) was used to generate a variety of deletion 
mutants of the receptor in order to identify and further 
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FIG. 1. Schematic diagram of the full-length wild type hu- 
man AR1 expression vector. The 3.1-kilobase full codingsequence 
of human AR was inserted  into  the  pCMV5  expression vector (4.2 
kilobases) at   the BglII and  HindIII  sites.  The  HindIII  site  was  lost 
due  to  blunt  end ligation. The  insert  was digested with BspHI, made 
blunt ended, and digested with BglII prior  to  insertion.  The ligated 
vector  was used to  transform  DH5 E. coli and was  sequenced  directly 
using single-stranded sequencing  from  the fl origin. Several  restric- 
tion enzyme sites unique to the vector and coding sequence are 
indicated. The vector contains  the cytomegalovirus promoter (CMV) ,  
the  human growth hormone  transcription  termination  and polyade- 
nylation signal (hGH), the SV40  origin of replication (SV 40),  the fl 
origin of replication, and  the ampicillin resistance gene (amp). The 
entire AR expression  vector, designated AR1, is 7.3 kilobases ( k b )  in 
length  and was used as parent vector for  site-directed mutagenesis. 
analyze domains required for receptor function. The restric- 
tion enzyme sites  indicated  in Fig. 1 facilitated the construc- 
tion of  AR mutants since they were unique to  the AR coding 
sequence and  the vector. NH2-terminal deletion mutants were 
created by exonuclease I11  digestion and contained  a  consen- 
sus translation  initiation sequence positioned 5‘ and in-frame 
to  the coding sequence. NH2-terminal deletions at  the KpnI 
site retained an  internal consensus  initiation sequence (50) at  
methionine 507. Several internal deletions were created using 
PCR mutagenesis as described under  “Experimental Proce- 
dures.” 
Transient Expression of Mutant  AR  Proteins  in COS Celk- 
Mutant AR proteins expressed in COS cells were analyzed on 
immunoblots to determine their approximate molecular 
weights. Two antipeptide  antibodies  facilitated AR detection: 
one was raised against  a 15-amino acid sequence (amino acids 
544-559) adjacent to  and 5’ of the DNA binding  domain (51) 
positioned in exon B (52); a second antibody was to a 21- 
amino acid peptide near  the  NH2  terminus (amino acids 9- 
29) (39). The full-length wild type receptor migrated as a 
doublet of 114 and 108 kDa (Fig. 2, lane Z), possibly reflecting 
different degrees of receptor phosphorylation.2 Expression of 
AR mutants containing major domain truncations or serial 
deletions of the NH2-terminal  domain  resulted in AR proteins 
reduced in size as shown in Fig. 2 for AR2, -3, -4, and -5 
(lanes 3-6). The smallest AR mutant with deletions of both 
the NH2- and COOH-terminal  domains was approximately 20 
kDa (Table I ) .  An internal deletion of a putative nuclear 
translocation signal ( A B ,  see below) resulted also in  a doublet 
of 107 and 102 kDa (Fig. 2, lane 7), again likely resulting from 
receptor phosphorylation. Controls for nonspecific interac- 
tions of antibody included preadsorption of antibody with 
peptide (data  not shown) and analysis of cell extracts  trans- 
fected with the parent vector lacking an AR cDNA insert 
(Fig. 2, lane 1). Neither  control resulted in  staining of prom- 
inent bands as also shown previously (39). AR mutant con- 
structs AR6 and AR7 (Table 11) lacked both antibody epi- 
topes, and therefore  these two expressed proteins could not 
be assessed for molecular size using the immunoblot tech- 
nique. A summary of receptor sizes determined by immuno- 
blot analysis is provided in  Tables I and 11. 
Androgen  Binding-All truncated receptors displayed high 
J. A. Kemppainen, J. A. Simental,  and E. M. Wilson, unpublished 
observations. 
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FIG. 2. Immunoblot analysis of AR mutants expressed in 
COS cells. COS cells transfected with wild type and mutant AR 
vector DNA (10 pg/lO-cm dish) were maintained in 50% serum 
containing medium for 40 h. Cells were washed in  phosphate-buffered 
saline  and  harvested  in 200 pl of SDS gel sample buffer  (39).  Aliquots 
of 20 pl with mercaptoethanol  added  to 3% were boiled for 5 min, 
cooled to room temperature,  and layered on  an 8% polyacrylamide 
gel. Electrophoresis and immunoblot analysis were performed as 
described under  “Experimental Procedures.”  Molecular  weight mark- 
ers were run  on a parallel  lane  (not  shown). Cells were transfected 
with  the  parent  pCMV5 expression  vector  lacking  AR  sequence (lane 
I ) ,  AR1 (lane 2 ) ,  AR2 (lane 3 ) ,  AR3 (lane 4 ) ,  AR4 (lane 5), AR5 
(lane 6) ,  and  AR8  (lane 7). 
affinity androgen binding  characteristic of the wild type recep- 
tor if the carboxyl-terminal region was intact  as summarized 
in Tables I and 11. No binding of the  synthetic androgen, [3H] 
R1881, was detected with mutants AR11, AR12, or AR13 
lacking the carboxyl-terminal region (Table I ) .  Deletion of a 
23-amino acid region in the hormone binding domain dimin- 
ished, but did not abolish, androgen binding. Between 8 and 
25% of wild type binding activity was retained. This 23-amino 
acid deleted region shares sequence similarity with other 
steroid  receptors (41) and  has been reported to be a  site of 
interaction with the 90-kDa heat shock protein (48). 
Domain Requirements for Transcriptional Activation- 
Transcriptional activation  domains of the AR were identified 
by coexpression of wild type or deletion mutants with a 
reporter plasmid. Induction of chloramphenicol acetyltrans- 
ferase (CAT)  activity  under the control of the MMTV  pro- 
moter was androgen-dependent using wild type AR (Fig. 3). 
R1881 stimulated a 70-fold increase in induction of CAT 
activity. Deletion of the steroid binding domain (AR11) re- 
sulted  in  constitutive CAT activity a t  approximately 10% of 
wild type,  indicating that  the steroid binding domain represses 
transcriptional activity of wild type AR in the absence of 
androgen. This  constraint is lost with deletion of the steroid 
binding domain. Furthermore, the low level of constitutive 
activity achieved with the  ARll deletion mutant is consistent 
with the presence of a transcriptional activation function 
within the steroid binding domain itself. Deletions of the 
entire NHp-terminal domain either with (AR7) or without 
(AR5) deletion of the DNA binding domain were totally 
lacking in  transcriptional  activation activity (Fig. 3, Table 11) ,  
suggesting that  the NH2-terminal domain has a role in mod- 
ulating  promoter activity. These results are summarized in 
Table I .  Essentially identical results were obtained using the 
reporter vector, pMTV29VTM (33, 53), which contains two 
glucocorticoid response elements from the MMTV long ter- 
minal repeat spaced 29 residues apart and linked to the 
thymidine  kinase promoter. 
To  further map  transcriptional  activator  signals  within the 
NH2-terminal domain, each of a series of NH2-terminal dele- 
tion  mutants was coexpressed with the MMTV-CAT reporter 
plasmid. As shown in Fig. 4, full inductive activity was re- 
tained with deletion of  72 (ARZ) and 141 (AR3) amino acids 
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TABLE I 
Functional  analysis of mutant  human  androgen receptors 
AR mutant DNAs  were constructed and tested as described under “Experimental Procedures.” The inclusive 
amino acid numbers (AA#) are indicated for each followed by the approximate molecular weights (MW (kD)) 
determined by migration on immunoblots of extracts from COS cells expressing mutant receptors. Binding of 3H] 
R1881 was determined by whole cell labeling and indicated by the presence (+) or absence (-) of high affinity 
binding activity. In cells expressing AR10, a mutant with partial deletion of the steroid binding domain, binding 
of [3H]R1881 was reduced to 8-25% of control (+). Subcellular localization was determined by transient expression 
of wild type and  mutant AR in  transfected COS cells in the presence (+A) or absence (-A) of 50 nM R1881 as 
described under  “Experimental Procedures.” Immunostaining of COS cells is indicated as either nuclear (N) or 
perinuclear and cytoplasmic (C), with some AR mutants localized in both, e.g. C>N or N>C. Functional activity 
was determined by transient cotransfection of mutant AR vector DNA and a reporter plasmid containing the 
MMTV-CAT fusion gene. CAT activity was determined from transfected CV1 cells incubated in the presence (+) 
or absence (-) of 50 nM R1881. Activity is expressed as a percentage relative to wild type AR1. 
A * #  MW R I M 1  Subcellular MMTVCAT 
N-Terminal DNA Hormone 
(LD) Blndlna Loc.11z.llon 
.A +A 4 +A 
A R l  1 A D t E [ F [ G I H (  1-919 1 1 4  C N 4 1 0 0  
AR8 I H?a I I I I I  A 6 2 8 - 6 5 7   1 0 7  C C,N <1 1 0 0  
ARO 507-919 33 
A828-657 
N N <1 4 
ARlO  507-019 37 ( + )  N N c l  ‘1 
&715-737 
A R l l  l - 6 W   8 7  N N 1 3  10 
AR12 I 1 1 - 5 M  70 N N 4 4 
AR13  507-660 Xi N N 1  2 
TABLE I1 
Functional  analysis of NH2-terminal  deletion  mutants of the  human androgen  receptor 
A series of NH2-terminal deletions was created using unidirectional exonuclease I11 digestion of  wild type AR1 
as described under  “Experimental Procedures.” Functional activities of the  mutant receptors were analyzed as 
described in the Table  I legend and under “Experimental Procedures.” Mutants AR6 and AR7 lacked the antibody 
epitope for the polyclonal antibody AR52  which  lies NH2-terminal of the DNA binding domain; molecular weights 
of these two expressed protein mutants could therefore not be determined by immunoblot analysis. All NH2- 
terminal deletions retained high affinity binding of [3H]R1881. 
A A #  Mw R I M 1  Subsdlulmr MYN-CAT 
(LD) Blndlna LocaIIzatlon 
N-Terminal LxIy\ Hormone -A +A  - +A 
AR1 I A D IE F 10 IH ]  1.919 114 C N 4 1 0 0  
AR2 I I I I ]  73-919  97 C N 4 100 ‘ .: :!$ 
AR3 I I I I I I  1 4 1 - 0 1 9  81 N A  N 4 1 0 0  
AR4 
ARS I l l  507-919  41  N N 4 4 
from  the  NH,  terminus. However, deletion of 338 amino  acids 
(AR4) or further  deletions (AR5, -6, and -7, see  also Table 11) 
caused  complete  loss of transcriptional activity. Thus, a region 
of the AR between amino  acids 141 and 338 appears  to  contain 
a signal  sequence essential for transcriptional  activation.  This 
region contains sequences rich in acidic residues similar  to 
the glucocorticoid receptor (30) and  yeast  transcription  fac- 
tors GCN4 and GAL4 (54,55). 
Since the NH2-terminal transcriptional activator signal 
may interact with nuclear  proteins involved in  transcriptional 
initiation, we tested whether the transcriptionally inactive 
mutant AR12 expressing only the  NH2-terminal  domain could 
inhibit  transcriptional  activation by wild type AR1.  AR12 and 
AR1 vector DNA were cotransfected  together with the 
MMTV-CAT  reporter plasmid into CV1 cells, and CAT ac- 
tivity was determined by eluting  the major  radioactive spots 
from thin layer chromatography plates. Inhibition of wild 















FIG. 3. Functional analysis of wild type AR and receptor 
mutants lacking major domains. CV1 cells  were transfected with 
parent or AR vector  DNA using  the calcium phosphate  precipitation 
method.  Immediately after  transfection, cells were placed in medium 
containing 0.2% serum with (+) or without (-) 50 nM R1881 and 
incubated for 24 h. Medium  was  replaced, and  after  an  additional 24 
h of incubation, the cells were harvested  and  assayed for CAT  activity 
as described under  “Experimental Procedures.” Quantitative  evalua- 
tion of CAT activity is provided in  Table I. 
- V  
[+ 
FIG. 4. Functional analysis of NH2-terminal deletion mu- 
tants of the AR. CV1 cells  were transfected  and  incubated  in  the 
presence (+) or absence (-) of 50 nM R1881 as described in Fig. 3 
and under “Experimental Procedures.” 
equal molar amounts of these vector DNAs were cotrans- 
fected. Inhibition increased to 55% when a 10- or 20-fold 
higher level of AR12 DNA was cotransfected  relative to AR1. 
Both AR5 and AR13, which contain  the DNA binding  domain, 
could fully inhibit CAT activity of wild type AR1 (data  not 
shown). 
Immunocytochemistry of Expressed AR Mutants-The  sub- 
cellular distribution of AR and  its  mutant  forms  was  investi- 
gated by transient expression in COS cells in  the  presence or 
absence of androgen. In a control  study  in which cells were 
transfected with the  parent pCMV5 vector lacking AR se- 
quence, minimal background staining was  observed with or 
without androgen  (Fig. 5, A and B ) .  Wild type AR displayed 
strong nuclear immunostaining  in  the  presence of R1881 (Fig. 
5D), but  in  the  absence of androgen, nuclear staining was 




FIG. 5.  Immunocytochemical localization of wild  type and 
mutant AR expressed in COS cells. COS cells were plated  in two- 
chamber microscope slides and transfected with 0.5 pg of DNA/ 
chamber using the  DEAE-dextran method.  Immediately after  trans- 
fection, the cells were incubated in 5% serum and the next day 
changed  to serum-free, phenol red-free  medium  with or without  the 
addition of 50 nM R1881. Twenty-four h later, R1881 was again  added 
to  the  hormone-containing medium, and  after 2  h the cells were fixed 
and  stained  using  the avidin biotin peroxidase  procedure as described 
under  “Experimental Procedures.” Shown  is  the  immunostaining of 
cells containing  the  parent pCMV  vector  lacking AR sequence with- 
out ( A )  or with ( B )  R1881; full-length, wild type  AR1 without (C) or 
with (D) R1881; AR8 without ( E )  or with (8’) R1881; and AR5 
without ( G )  or with (H) R1881. The left panels lack hormone  treat- 
ment,  and  the right panels were treated for 24 h  with 50 nM R1881. 
the  perinuclear region of the cytoplasm (Fig. 5C). Subsequent 
addition of androgen 2 h prior  to  fixation  resulted  in a shift 
from  the cytoplasmic/perinuclear region to  the nucleus (data 
not shown). These results suggest that AR undergoes hor- 
mone-dependent  translocation from the  cytoplasmic/perinu- 
clear region to the nucleus. In control transfection studies 
using  the  same  staining  conditions for the progesterone and 
estrogen receptors in the absence of hormone, very little 
cytoplasmic/perinuclear staining was  observed like that seen 
for the AR. The estrogen and progesterone receptors were 
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located in  the nucleus both  in  the  absence  and  presence of 
hormone  as previously reported (14, 35, 36, 38). The gluco- 
corticoid receptor was both  cytoplasmic  and  nuclear  in  the 
absence of hormone  with a  major portion of receptor  in  the 
cytoplasm;  staining  shifted  to  the nucleus with  hormone  ad- 
dition.  Previous  reports  have  indicated a predominantly  cy- 
toplasmic distribution of the glucocorticoid receptor in the 
absence of hormone  (13,38,56). 
Progressive deletion of the  NH2  terminus  resulted  in  in- 
creased nuclear immunostaining  in  the  absence of androgen, 
beginning  with deletion of 211 amino  acids (AR3, Table 11). 
Mutant AR5 which lacks almost the entire NHz-terminal 
domain localized in the nucleus both in the absence and 
presence of androgen (Fig. 5, G and H). Deletion of the 
COOH-terminal  domain  (AR11  and -12) or the  COOH-  and 
NHz-terminal  domains (AR13)  also resulted  in  constitutively 
nuclear AR (Table  I).  Thus,  the  NHp-terminal  and carboxyl- 
terminal regions of AR act  to  inhibit  nuclear  transport of the 
unliganded receptor. This  inhibition  is released by androgen 
binding in the wild type  receptor or by deletion of the major 
domains. This inhibition could result from specific protein 
interactions or a size constraint.  It was somewhat  surprising 
that the NHz-terminal domain alone (AR12) was nuclear 
(Table  I).  In  this  instance,  the  truncated AR protein,  with  an 
estimated molecular mass of 70 kDa  (Table  I),  must  be  small 
enough to pass unimpeded through nuclear pores. In the 
absence of a DNA binding sequence, it may nevertheless 
remain associated with the nucleus due to protein/protein 
interactions. 
A Nuclear Targeting Signal  in AR-Sequence requirements 
for nuclear translocation of AR were further investigated 
using  site-directed  mutagenesis  and immunocytochemistry.  A 
sequence  located  between amino  acids 628 and 657 within  the 
hinge region of AR contains  short  stretches of basic amino 
acids that resemble nuclear targeting signals (NTS) of the 
glucocorticoid receptor (13) and the SV40 large T antigen 
(55). A comparison of this sequence with other published 
NTS is shown in Table 111. PCR mutagenesis was used to 
prepare two mutant AR vectors: a full-length AR lacking 32 
amino acids in  the hinge region of the D  exon (AR8), shown 
diagrammatically  in Fig. 6, and a mutant lacking this  same 
sequence and most of the  NH,-terminal  domain (AR9, Table 
I). Deletion of the  putative  NTS  from  the  full-length  receptor 
(AM) increased  cytoplasmic/perinuclear  staining  in  the  pres- 
ence of androgen  and  markedly reduced, but  did  not abolish, 
nuclear  staining (Fig. 5F). The  striking  perinuclear  staining 
of AR8 in the presence of androgen was also observed by 
immunofluorescence  (Fig. 7 B )  in  marked  contrast  to  andro- 
gen-induced nuclear localization of the full-length wild type 
receptor (Fig. 7A). These  results  indicate  that  the  NTS  po- 
tentiates androgen-dependent nuclear uptake of the full- 
length wild type AR and  that absence of the NTS reduces the 
androgen  stimulus for nuclear  translocation of AR. Deletion 
of NTS from AR5 did  not  alter  its  constitutive nuclear loca- 
tion (see AR9, Table  I). 
An experiment was  designed to  determine if two mutants, 
AR8 and AR5, might interact such that the NTS of AR5 
would assist  in  nuclear  translocation of AR8 which lacks the 
putative  NTS.  The AR antibody raised against a NHz-termi- 
nal epitope was used so that only AR8 would be detected 
immunocytochemically. Staining in the presence of androgen 
remained predominantly perinuclear. Thus, it can be con- 
cluded that  either  the two mutant ARs  did not  interact or the 
NTS of AR5 could not accommodate nuclear transport of 
AR8. AR5 alone is constitutively  nuclear  and  lacks  the  NH2- 
terminal  domain. 
The functional activity of mutant receptors lacking the 
NTS was assessed in  cotransfection assays. Deletion of NTS 
from wild type AR resulted in androgen-dependent CAT 
activity  similar  to wild type (Fig. 8). This  result was surprising 
since transfection studies in COS cells revealed predomi- 
nantly  cytoplasmic/perinuclear  staining even  in the presence 
of androgen. However,  since there was not  total loss of nuclear 
transport with deletion of the  NTS, a low level of receptor 
entering  the nucleus may have  been  sufficient  for  full induc- 
tion of CAT activity. A similar  retention of activity by the 
large T antigen  after  deletion of a homologous NTS  has been 
reported (57, 58).  In  the  mutant  lacking a NTS  and  the  NHz- 
terminal  domain, complete loss of CAT  activity was observed 
(Fig. 8). 
DISCUSSION 
Deletion mutagenesis  and  expression of human AR cDNA 
has  facilitated  functional  analysis of the AR domains, includ- 
ing regions  for hormone  binding, nuclear transport,  and  tran- 
scriptional  activation.  As  predicted from  previous studies  on 
a partial AR cDNA  (42)  and  from homology considerations 
within the family of steroid receptors (1, 4), high affinity 
hormone  binding was restricted  to  the carboxyl one-third of 
the  protein.  Hormone  binding  in  this region was required  for 
t anscriptional  activity of the  full-length, wild type  human 
AR. This  hormone  requirement was lost, however, with  dele- 
tion of the  carboxyl-terminal region, resulting  in a constitu- 
tively active regulatory protein with 10% of the transcrip- 
tional  enhancement  activity of wild type AR. Thus,  the  steroid 
binding domain represses transcriptional activation in the 
TABLE I11 
Comparative alignment of nuclear localization signals 
Amino acid numbers are indicated for the first residue of each sequence containing the putative nuclear 
localization  signal. The SV40 large T antigen  sequence  has served as a model for nuclear  targeting  signals (55). 
The  amino acid sequence shown for human AR immediately follows the  DNA  binding  domain  and begins the 
hinge  region. The  rat glucocorticoid receptor sequence (13) extends 11 amino  acids  into  the  DNA  binding  domain 
and  continues  into  the hinge region preceding the  steroid  binding  domain. Additional homologous sequences are 
shown for the rabbit progesterone receptor (14), the  human c-myc (79), yeast histone H2B (801, and Xenopus 
nucleoplasmin (81). All sequences have stretches of basic amino acids that characterize nuclear translocation 
signals. 
Protein Amino acid no. Sequence 
SV40 large T antigen 126 PKKKRKV 
Human  androgen receptor 627 GARKLKKLGNLKLQEEGEASSTTSPTEETTQK 
Rat glucocorticoid receptor 497 YRKCLQAGMNLEARKTKKKIKGIQQAT 
Rabbit  progesterone receptor 638 RKFKKFNK 
Human c-myc 320 
Yeast histone H2B 28 
PAAKRVKLD 
DGKKRSR 
Xenopus  nucleoplasmin 160 GQAKKKKLD 
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627 OARKLKKLGNLKLOEEOEASSlTSFTEElTOK 6 5 8  
Nuclear Transporl Signal 
FIG. 6. A putative nuclear targeting signal for AR. A 32- 
amino acid sequence was deleted based on homology comparisons 
with  the glucocorticoid receptor and  the  SV40 large T antigen  nuclear 
targeting signals. This region was deleted from the  full-length AR to 
create AR8. 
FIG. 7. Immunofluorescent localization of AR in COS cells. 
COS cells were transfected with either  the full-length, wild type  AR1 
(A) or the deletion mutant  AR8 ( B )  which lacks  the  putative  nuclear 
targeting signal shown in Fig. 6. After transfection, the cells were 
maintained in medium containing 0.2% serum and 50 nM R1881. 
Immunofluorescent staining was  performed as described under  “Ex- 
perimental Procedures.” 
R1881 I - + ,, - + I, - + ,( - + I 
pCMV ARI  AR8  AR9 
FIG. 8. Functional activity  of  wild type and mutant recep- 
tors lacking the putative nuclear targeting signal. CV1 cells 
were transfected as described under  “Experimental  Procedures”  and 
incubated in the presence or absence of R1881 as indicated.  Shown 
is  CAT  activity for the  parent pCMV  plasmid, wild type ( A R I ) ,  full- 
length AR  lacking the  NTS (AR8),  and  the  NH2-terminal  and NTS 
deletion (AR9).  The upper spots represent  acetylated  forms of [’‘C] 
chloramphenicol. 
absence of androgen and thereby regulates the activator  ca- 
pability of  AR. The overall reduction in  transcriptional  activ- 
ity upon deletion of the steroid binding domain suggests that 
this region itself contains  one or more transcriptional  acti- 
vator signals. Alternatively, this domain may influence overall 
receptor conformation necessary for full transcriptional acti- 
vation. Similar inhibition by the steroid binding domain has 
been reported for the glucocorticoid (59, 60), estrogen (61, 
62), progesterone (63), and vitamin  D  receptors (9)  and, most 
recently, for the AR (64). 
A concerted interplay among other domains of AR was 
observed in addition to  the steroid binding domain. The DNA 
binding domain presumably anchors the receptor to its hor- 
mone response element, which in these  studies was contained 
within the MMTV long terminal repeat. The DNA binding 
domain is also likely involved in receptor dimerization as 
demonstrated  with other steroid  receptors (15, 26, 65). This 
domain is essential for transcriptional activation by steroid 
receptors (1, 7, 25, 61, 66, 67) and may contain an intrinsic 
activator  function (25). The low but detectable CAT activity 
(1% of  wild type AR) when the AR DNA binding domain was 
expressed without the COOH- or NH2-terminal domains sup- 
ports  this hypothesis. Moreover, single base mutations  in the 
second zinc finger region of the glucocorticoid receptor were 
reported to result  in loss of transcriptional  enhancer activity 
without affecting specific DNA binding (68). A  three-dimen- 
sional model depicting  interaction of the glucocorticoid recep- 
tor DNA binding domain with its response element indicates 
several amino acids in the second zinc fingers of the homo- 
dimer are potentially available for contact with proteins of 
the  transcriptional complex (69). 
The NH2-terminal domain of AR was essential for gene 
activation, shown here by loss of trancriptional activity with 
deletion of the  first 338 amino acids. Similar  transcriptional 
activator  functions are reported  in  NH2-terminal regions of 
the glucocorticoid and progesterone receptors that resemble 
AR in being relatively hydrophilic and negatively charged. A 
40-kDa mutant glucocorticoid receptor, nt‘, which lacks the 
NH2-terminal domain, is biologically inactive even though it 
contains both hormone and DNA binding domains (5,70,71). 
Acidic regions between amino acids 77 and 293 of the human 
and mouse glucocorticoid receptor (6, 25, 30, 66) and within 
this region, amino acids 106-318, enhanced transcription (28, 
29). A 50% reduction in transcriptional enhancement was 
observed following deletion of 128 amino acids from the NH2 
terminus of the chicken progesterone receptor, which also 
includes a highly acidic region, while cleavage of the  entire 
NHP-terminal region abolished transcriptional  activity (7). A 
smaller deletion (amino acids 262-287) in  a conserved area 
near  a  potential leucine zipper motif also reduced transcrip- 
tional activation by the progesterone receptor (67). Although 
these regions may be directly involved in transcriptional 
activation, it  cannot be ruled out  that such  deletions change 
the conformation of the remaining receptor to make it tran- 
scriptionally inactive. 
The mechanisms involving NH2-terminal sequences of ste- 
roid receptors in gene activation are unknown; however, pro- 
tein/protein interactions likely occur with other transcription 
factors  (33,34).  Both  promoter and host cell specificity appear 
to influence the requirement for the NH2-terminal domains 
in transcriptional activation (27, 31, 32, 61, 62), suggesting 
that these regions interact with cell-specific transcription 
factors. The ability of the AR NH2-terminal domain to inhibit 
transcription when coexpressed in excess of wild type AR 
suggests that it competes for binding to one or more nuclear 
regulatory proteins required for activation of transcription 
initiation.  NH2-terminal domain sequences are  the most  di- 
vergent among the family of steroid receptors (1,4). Even the 
rat  and  human AR differ significantly in this region, primarily 
by the presence and length of repeated single amino acid 
motifs (41, 52). Sequence specificity among steroid receptors 
in  this domain contrasts with the striking sequence similarity 
in  other regions, particularly the DNA binding domain. I t  is 
therefore the NH2-terminal domain that may contribute to 
specificity of gene activation by steroid hormone receptors 
through  interaction with specific transcription factors. 
A surprising finding of these studies was the subcellular 
localization of  AR expressed in COS cells. In  the absence of 
hormone, AR  was predominantly cytoplasmic, with staining 
largely in the perinuclear region. Immunofluorescent studies 
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further revealed the ligand-free AR in cytoplasmic  organelles 
surrounding  the nucleus,  possibly  vesicles of the  endoplasmic 
reticulum  or Golgi, while androgen  caused  rapid  and complete 
nuclear  translocation. The glucocorticoid receptor  also  under- 
goes hormone-induced nuclear uptake (13, 38); however, in 
the absence of hormone, it was  distributed  more  uniformly 
through  the cytoplasm. In  control  studies  not  shown  in  this 
report,  the  estrogen,  progesterone,  and glucocorticoid  recep- 
tors were expressed in COS cells to assess whether  the  fixation 
and  staining  procedures  contributed  to  the  perinuclear  distri- 
bution of AR. As reported previously by others,  estrogen  and 
progesterone receptor immunostaining was nuclear in the 
absence of hormone (14, 35, 38, 72), and using the same 
conditions,  the glucocorticoid receptor was cytoplasmic (13, 
38, 56), with  some nuclear  and  minimal  perinuclear  staining. 
Thus  the  striking  perinuclear  staining of AR does not  appear 
to  result  from  fixation  or  staining  procedures  and  indicates 
that  the subcellular  localization of the ligand-free AR differs 
from  that of the  other major steroid receptors. 
The  transfection  system described in  this  report was useful 
in establishing a sequence required for nuclear transport 
within  the hinge region 3’ of the  DNA  binding  domain.  In 
the absence of this  putative  nuclear  targeting signal, the AR 
remained predominantly cytoplasmic. The inability of the 
ligand-free AR or  the  androgen-bound AR lacking  the  NTS 
to  enter  the nucleus  suggests the  presence of a nuclear  barrier. 
Size constraints are thought to limit protein access to  the 
nucleus; 60-kDa or smaller proteins diffuse freely into the 
nucleus while larger proteins  require  nuclear  targeting mech- 
anisms (58, 73). In agreement with this hypothesis, large 
deletions of AR rendered  it  constitutively nuclear. The  puta- 
tive  targeting  signal  shown  here  shares homology with  those 
of other  steroid receptors. Targeting  signals of the glucocor- 
ticoid receptor are located within two  domains: one  in close 
association  with  the  DNA  binding  domain  and homologous 
in sequence to  the SV40  large T antigen  (13),  and  the  other 
in  the  carboxyl-terminal  steroid  binding  domain.  While  the 
receptors for progesterone, glucocorticoid, and mineralocor- 
ticoid  share homologous sequences  with the large T antigen 
nuclear  targeting signal, the  estrogen,  vitamin D, thyroid,  and 
retinoic acid receptors have less homologous sequences (4), 
suggesting  a different  mechanism for nuclear  uptake. I t  may 
be significant that  this  latter  group of receptors is smaller  in 
size due  to  shorter  NHz-terminal sequences. 
High-level transient expression of AR in COS cells con- 
trasts  with  the low concentration of AR in  androgen-respon- 
sive cells. Light microscopy immunocytochemical analyses of 
reproductive tract  tissue  sections from intact  male  rats  have 
demonatrated AR in nuclei (41, 51).3 In  tissue  sections  from 
rats 1 day  after  castration  to remove the  source of endogenous 
androgen,  nuclear  staining  remained  detectable  but  somewhat 
diminished (74).‘ Three days after castration, AR became 
immunocytochemically ~ndetectable.~  Strong nuclear  im- 
munostaining  restored  within 15 min of androgen  administra- 
tion  to  castrated rats:’ indicated  that AR remains  in  tissues 
following castration  as  supported by  ligand binding  studies of 
cytosol fractions (75-78). Persistence of nuclear  staining 24 
h after  castration  (74)3 may  reflect  delayed clearance of nu- 
clear AR after  androgen  depletion by castration.  The  presence 
of other androgen binding proteins (55) may contribute to 
more  prolonged local elevation of androgen  after  castration 
in  certain  tissues,  particularly  rat  ventral  prostate.  Thus,  the 
subcellular  localization of endogenous androgen-free AR re- 
mains  uncertain  due  to  what  appears  to  be low reactivity  with 
Sar, M., Lubahn, D. B., French,  F. S., and Wilson, E. M. (1990) 
Endocrinology, in  press. 
antibody when  assayed  immunocytochemically. 
Acknowledgment-We thank  Jon  Kemppainen for  excellent tech- 
nical assistance  and D. 0. Toft, G. L.  Greene, J. A. Gustafsson, and 
M. V. Govindan for  other  steroid receptor antibodies  and cDNA used 
in  control studies. 
REFERENCES 
1. Evans, R. M. (1988) Science 240,889-895 
2. Yamamoto, K. R. (1985) Annu.  Rev.  Genet. 19, 209-252 
3. Green, S., and  Chambon,  P. (1986) Nature 324, 615-617 
4. Carson-Jurica, M. A,, Schrader, W. T., and O’Malley, B. W. 
5. Danielsen, M., Northrop, J .  P., and Ringold,  G. M. (1986) EMEO 
6. Giguere, V., Hollenberg, S. M., Rosenfeld, M. G., and  Evans, R. 
M. (1986) Cell 46, 645-652 
7. Gronemeyer, H., Turcotte, B., Quirin-Stricker, C., Bocquel, M. 
T., Meyer, M. E., Krozowski, Z., Jeltsch, J. M., Lerouge, T., 
Garnier, J. M., and Chambon, P. (1987) EMEO J.  6, 3985- 
3994 
8. Carson, M. A., Tsai, M. J., Conneely, 0. M., Maxwell, B. L., 
Clark, J .  H., Dobson, A.  D.  W., Elbrecht, A., Toft, D. O., 
Schrader, W. T., and O’Malley, B. W. (1987) Mol.  Endocrinol. 
1, 791-801 
9. McDonnell, D. P., Scott, R. A., Kerner, S. A., O’Malley, B. W., 
and  Pike, J. W.  (1989) Mol. Endocrinol. 3, 635-644 
10. Weinberger, C., Thompson, C.  C., Ong, E. S., Lebo, R., Gruol, D. 
J.,  and  Evans, R.  M. (1986) Nature 324, 641-646 
11. Green, S., Kumar, V., Krust, A., Walter, P., and Chambon, P. 
(1986) Cold Spring Harbor Symp. Quant. Eiol. 51, 751-758 
12. Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, 
B. L., Housman, D.  E., and  Evans, R. M. (1987) Science 237, 
268-275 
13. Picard, D., and Yamamoto, K. R. (1987) EMEO J.  6, 3333-3340 
14. Guiochon-Mantel, A., Loosfelt, H., Lescop, P., Sar, S., Atger, M., 
Perrot-Applanat, M., and Milgrom, E. (1989) Cell 57, 1147- 
1154 
(1990) Mol. Endocrinol. 11, 201-220 
J. 5,2513-2522 
15. Kumar, V., and  Chambon,  P. (1988) Cell 55, 145-156 
16. Fawell, S. E., Lees, J .  A,, White, R., and Parker, M. G. (1990) 
Cell 60,953-962 
17. Schena, M., Freedman, L. P.,  and Yamamoto, K. R. (1989) Genes 
& Dev. 3,1590-1601 
18. Quigley, C. A., Simental, J. A., Evans, B. A., Lubahn, D. B., 
Hughes, I. A., and French, F. S. (1990) 72nd Meeting of the 
Endocrine Society, Atlanta, Abstracts, p. 223, The Endocrine 
Society, Bethesda,  MD 
19. French, F. S., Lubahn, D. B., Brown, T. R., Simental, J. A., 
Quigley, C. A,, Yarbrough, W. G., Tan,  J .  A., Sar, M., Joseph, 
D.  R., Evans, B. A. J., Hughes, I. A., Migeon, C. J.,  and Wilson, 
E. M.  (1990) Recent  Prog. Horm. Res., in press 
20. Hughes, M. R., Malloy, P. J., Kieback, D. G., Kesterson, R. A,, 
Pike, J .  W., Feldman, D., and O’Malley, B. W. (1988) Science 
242, 1702-1705 
21. Green, S., Kumar, V., Theulaz, I., Wahli, W., and Chambon, P. 
22. Danielsen, M., Hinck, L., and Ringold, G. M. (1989) Cell 57, 
23. Umesono, K., and  Evans, R. M. (1989) Cell 57, 1139-1146 
24. Miesfeld, R., Godowski, P. J., Maler, B. A., and Yamamoto, K. 
R. (1987) Science 236,423-427 
25. Hollenberg, S. M., Giguere, V., Segui, P.,  and  Evans, R. M. (1987) 
Cell 49, 39-46 
26. Tsai, S. Y., Carlstedt-Duke, J., Weigel, N. L., Dahlman, K., 
Gustafsson, J .  A., Tsai,  M. J., and O’Malley, B. W. (1988) Cell 
55, 361-369 
27. Tora,  L., Gronemeyer, H., Turcotte, B., Gaub, M. P.,  and  Cham- 
bon, P. (1988) Nature 333, 185-188 
28. Godowski, P.  J.,  Picard, D., and Yamamoto,  K.  R.  (1988) Science 
241, 812-816 
29. Freedman, L. P., Yoshinaga, S. K., Vanderbilt, J .  N., and Ya- 
mamoto, K. R. (1989) Science 245, 298-300 
30. Hollenberg, S. M., and  Evans, R. M. (1988) Cell 55, 899-906 
31. Lees, J. A., Fawell, S. E., and  Parker, M. G. (1989) Nucleic  Acids 
32. Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer,  E., 
(1988) EMBO J. 7,3037-3044 
1131-1138 
Res. 17,5477-5488 
and  Chambon,  P. (1989) Cell 59, 477-487 
518 Mutagenesis  and  Functional  Analysis of the  Androgen Receptor 
33. Strahle, U., Schmid, W., andschutz, G. (1988) E M B O J .  7,3389- Gustafsson, J .  A. (1987) Endocrinology 120 ,  1232-1242 
34. Mitchell,  P.J. and  Tjian, R. (1989) Science 245 ,  371-378  2127 
35. King, W. J., and Greene, G. L. (1984) Nature 307, 745-747 58. Hunt,  T. (1989) Cell 59, 949-951 
36. Welshons, W.  V., Lieberman, M. E., and Gorski, J .  (1984) Nature 59. Oro, A. E., Hollenherg, S. M., and Evans, R. M. (1988) Cell 5 5 ,  
37. Perrot-Applanat, M., Logeat, F., Groyer-Picard, M. T.,  and Mil- 60. Picard, D., Salser, S. J., and Yamamoto, K. R. (1988) Cell 5 4 ,  
grom, E. (1985) Endocrinology 116 ,  1473-1484 1073-1080 
38. Picard, D., Kumar, V., Chamhon, P., andyamamoto, K. R. (1990) 61. Kumar, V., Green, S., Stack, G., Berry, M., Jin, J. R., and 
Cell Reg. 1, 291-299 Chambon, P. (1987) Cell 51,941-951 
39. Quarmby, V. E., Kemppainen, J. A., Sar, M., Luhahn, D. B., 62. Bocquel, M. T., Kumar, V., Stricker, C., Chambon, P., and 
French, F. S., and Wilson, E. M. (1990) Mol. Endocrinol. 4, Gronemeyer, H. (1989) Nucleic  Acids Res. 17,  2581-2595 
40. Yarbrough, W. G., Quarmby, V. E., Simental, J. A., Joseph, D. T., Meyer, M. E., Krozowski, Z., Jeltsch, J. M., Lerouge, T., 
R., Sar, M., Luhahn, D. B., Olsen, K. L., French, F. S., and Garnier, J. M., and Chamhon, P. (1987) E M B O  J.  6 ,  3985- 
Wilson, E. M. (1990) J.  Biol.  Chem. 265,8893-8900 3994 
41. Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J. A., Higgs, H. N., 64. Rundlett, s. E., WU, x. p., and Miesfeld, R. L. (1990) Mol. 
Larson, R. E., French, F. S., and Wilson, E. M. (1988) Mol. Endocrinol. 4 ,  708-714 
Endocrinol. 2 ,  1265-1275 65. Wrange, O., Eriksson,  P., and  Perlmann, T. (1989) J.  Biol. Chern. 
42. Lubahn, D.  B., Joseph, D.  R., Sullivan, P. M., Willard, H. F., 264,5253-5259 
French, F. s., and Wilson, E. M. (1988) science 240, 327-330 66. Daniel-, M., Northrop, J. P., Jonklass, J., and Ringold, G. M. 
43. Andersson, S., Davis, D. L., Dahlhack, H., Jornvall,  H.,  and (1987) Mol. Endocrinol. 1,816-822 
Russell, D. W. (1989) J. Biol.  Chern. 264,8222-8229 67. Dobson, A.  D. W., Conneely, 0. M., Beattie,  W., Maxwell, B. L., 
44. Henikoff, S. (1984) Gene (Amst.) 2 8 ,  351-359 Mak, P., Tsai, M. J., Schrader, W. T., and O'Malley, B. W. 
45. Higuchi, R., Krummel, B., and Saiki, R. K. (1988) Nucleic  Acids (1989) J.  Biol. Chern. 264,4207-4211 
68. Schena, M., Freedman, L. P., and Yamamoto, K. R. (1989) Genes 
46. Higuchi, R. (1989) in P C R  T e c h n o k y :  Principles and APP~~CU- 69, Hard, T., Kellenbach, E., Boelens, R., Maler, B, A,, Dahlman, C Deu. 3 ,  1590-1601 
K., Freedman, L. P., Carlstedt-Duke, J., Yamamoto, K. R., 
Gustafsson, J .  A,, and Kaptein, R. (1990) Science 249, 157- 
160 
70. Yamamoto, K. R., Stampfer, M. R., and Tomkins, G. M. (1974) 
Proc. Natl.  Acad.  Sci. U. S. A. 71 ,  3901-3905 
3395 57. Wildeman, A. G. (1989) Proc.  Natl.  Acad. Sci. U. S. A. 86, 2123- 
307 ,  747-749 1109-1114 
1399-1407 63. Gronemeyer, H., Turcotte, B., Quirin-Stricker, C., Bocquel, M. 
Res. 16,7351-7367 
tionsfor  DNA  Amplification (Erlich, H., ed) pp. 61-70, Stockton 
Press, New York 
47. Jones, D. H., and Howard, B. H. (1990) Biotechniques 8, 178- 
183 
48. Pratt, W. B., Jolly, D. J., Pratt, D.  V., Hollenherg, S. M., Giguere, 
v., CadePond, F. M., Schweizer-Groyer, G.7 Catelli, M. G.9 71, Gehring, u., and Am&, H, (1985) FEBS Lett, 179,  138-142 
267-273 
R. M., and Baulieu, E.  E. (1988) J. 2639 72. Elashry-Stowers, D., Zava, D. T., Speers, W. C., and Edwards, D. 
49. Sar, M. (1985) in Techniques in ImrnunocYtochernktV (Bullock, 73. Dingwall, c., and Laskey, R. A, (1986) Annu, Reu, Cell Bioi, 2, 
74. Husmann, D. A., Wilson, C. M., McPhaul, M. J., Tilley, W. D., 
and Wilson, J .  D. (1990) Endocrinology 126,2359-2368 
M., French, F. S., and Wilson, E. M. (1988) Mol. Endocrinol. 5620-5629 
52. Lubabn, D. B., Brown, T. R., Simental, J. A., Higgs, H. N., 6310-6319 
P. (1988) Cancer Res. 48, 6462-6474 
G. R., and  Petrusz, P., eds) Vol. 3, pp. 43-54, Academic Press, 
Orlando, FL 
367-390 
50. Kozak, M. (1984) Nature 308, 241-246 
51. Tan, J. A.3 Joseph, D. R., QuarmbY, v. E., Lubahn, D. B., Sar, 75. Wilson, E. M., and French, F. S. (1976) J.  Biol. Chem. 251 ,  
2, 1276-1285 76. Wilson, E. M., and French, F. S. (1979) J.  Biol. Chern. 254 ,  
Migeon, c .  J., Wilson, E. M., and French, F. s. (1989) Proc. 77. Wilson, E. M., Wright, B. T., and Yarbrough, W. G. (1986) J. 
Natl.  Acad.  Sci. U. S. A. 86,9534-9538 Biol. Chem. 261,6501-6508 
53. Strahle, U., Boshart, M., Klock, G., Stewart, F., and Schutz, G. 78. Lea, 0. A., Petrusz, p., and French, F. S. (1979) J.  Biol. Chem. 
(1989) Nature 339 ,  629-632 254,6196-6202 
54. Hope, I. A., Mahadevan, S., and  Struhl, K. (1988) Nature 333 ,  79. Dang, C .  V., and Lee, W.  M. (1988) Mol. Cell. Biol. 8,4048-4054 
55. Kalderon, D., Roberts, B. L., Richardson, W. D., and  Smith, A. and Hereford, L. M. (1987) Mol. Cell. Biol. 5,  2569-2576 
56. Wikstrom, A. C., Bakke, O., Okret, S., Bronnegard, M., and 2625 
635-640 80. Moreland, R. B., Langevin, G. L., Singer, R. H., Garcea, R. L., 
E. (1984) Cell 39 ,  499-509 81. Burglin, T. R., and DeRobertis, E. M. (1987) E M B O  J.  9, 2617- 
